Advertisement
Advertisement
Sight Sciences, Inc. (SGHT)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Follow
At close: 04:00PM EDT
After hours:
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 3.3000 |
| Open | 3.2900 |
| Bid | 3.2100 x 1000 |
| Ask | 3.4300 x 900 |
| Day's Range | 3.2100 - 3.4385 |
| 52 Week Range | 2.7800 - 15.2950 |
| Volume | |
| Avg. Volume | 206,403 |
| Market Cap | 163.954M |
| Beta (5Y Monthly) | 1.14 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.5300 |
| Earnings Date | Aug 03, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.60 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Subscribe to Yahoo Finance Plus to view Fair Value for SGHT
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Sight Sciences, Inc.Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.RatingFair ValueEconomic Moat3 days agoMorningstar
The FlyCVS upgraded, RTX downgraded: Wall Street's top analyst calls
CVS upgraded, RTX downgraded: Wall Street's top analyst calls
- Investing.com
4 big analyst cuts: RTX pelted with 2 downgrades on word of $3B hit
Monness, Crespi, Hardt lowered Oracle (NYSE:ORCL) to Neutral from Buy on Tuesday.
GlobeNewswireSight Sciences Provides Revenue Guidance for the Third Quarter of 2023 and Updates Revenue Guidance for Full Year 2023
MENLO PARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today announced third quarter 2023 revenue guidance and updated its revenue guidance for full year 2023. Third Quarter 2023 Revenue GuidanceThe Company expects third quarter 2023 total revenue to be in the range of $19.0
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2023 Yahoo. All rights reserved.
